Active substance sacituzumab govitecan
Holder Gilead
Status closed
Indication treatment in monotherapy of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease and with no adequate treatment options
Public documents Approbation
  Information for the patient
  Informed consent
Last update 21/12/2022


Last updated on 15/09/2023